A newly designed T cell engager antibody could become an effective treatment for patients with acute myeloid leukaemia (AML) who do not qualify for stem cell transplants, researchers have reported.
The treatment aims to counter the effects of the...
1 year ago
Improving lives in the haematology community.
That’s the ambitious aim of our next three-year strategy, which will launch in March.
As ever, there was much discussion about the title. A key point of debate is, “Where do patients fit into this?” Af...
1 year ago
